

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translation and the Japanese original, the original shall prevail.

February 13, 2024

To Whom It May Concern:

Company Name: Taisho Pharmaceutical Holdings Co., Ltd.
Head Office: 3-24-1, Takada, Toshima-ku, Tokyo
Representative: Akira Uehara, Chief Executive Officer
(TSE Standard Market: Code 4581)
Contact: Shinichi Tanaka, General Manager
Corporate Communications
(Tel: +81-3-3985-2020)

Notice Regarding Cancellation of Treasury Shares

The Company hereby announces that, at the meeting of the Board of Directors held today, the Company has resolved to cancel the treasury shares pursuant to Article 178 of the Companies Act (Act No. 86 of 2005, including subsequent amendments).

Such cancellation of the treasury shares is subject to the condition that the proposal for the share consolidation with an effective date of April 11, 2024, as stipulated in the Company's press release "Notice of Consolidation of Shares, Abolition of the Provision of Shares Constituting One Share Unit, and Partial Amendment to the Articles of Incorporation" dated as of today, will be approved and adopted as originally proposed at the Company's extraordinary general meeting of shareholders scheduled on March 18, 2024.

1. Class of shares to be cancelled: common shares of the Company
2. Number of shares to be cancelled: 3,103,572 shares (representing 3.65% of the total outstanding shares before cancellation)
(Note) Rounded to two decimal places.
3. Scheduled date of cancellation: April 10, 2024

(Note)

After cancellation, the total number of outstanding shares of the Company will be 82,036,081 shares. The number of shares to be cancelled mentioned above corresponds to all treasury shares held by the Company as of December 31, 2023.

[End]